Nuvilex Contracts With Inno Biologics, an FDA-Compliant Provider, for Initial Generation of Cloned Cells for Future Phase 3 Clinical Trials

Published: Sep 17, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SILVER SPRING, Md., Sept. 17, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX) ("Company"), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today it has contracted Inno Biologics Sdn. Bhd. to generate cell clones that are the basis of the Company's future Phase 3 cancer clinical trials.

Help employers find you! Check out all the jobs and post your resume.

Back to news